The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 22, 2017

Filed:

Sep. 19, 2014
Applicant:

Ibc Pharmaceuticals, Inc., Morris Plains, NJ (US);

Inventors:

Chien-Hsing Chang, Downingtown, PA (US);

David M. Goldenberg, Mendham, NJ (US);

Edmund A. Rossi, Woodland Park, NJ (US);

Assignee:

IBC Pharmaceuticals, Inc., Morris Plains, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/48 (2006.01); C07K 16/28 (2006.01); A61K 51/10 (2006.01); C07K 14/47 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 47/487 (2013.01); A61K 39/3955 (2013.01); A61K 47/484 (2013.01); A61K 47/4843 (2013.01); A61K 47/4863 (2013.01); A61K 47/48415 (2013.01); A61K 47/48423 (2013.01); A61K 47/48561 (2013.01); A61K 47/48569 (2013.01); A61K 51/1027 (2013.01); A61K 51/1045 (2013.01); C07K 14/47 (2013.01); C07K 2317/31 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2319/33 (2013.01); C07K 2319/70 (2013.01); C07K 2319/74 (2013.01);
Abstract

Disclosed herein are compositions and methods of use comprising hexavalent DNL complexes. Preferably, the complexes comprise anti-CD20 and/or anti-CD22 antibodies or fragments thereof. More preferably, the anti-CD20 antibody is veltuzumab and the anti-CD22 antibody is epratuzumab. Administration of the subject hexavalent DNL complexes induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. In most preferred embodiments, the DNL complexes increase levels of phosphorylated p38 and PTEN, decrease levels of phosphorylated Lyn, Akt, ERK, IKKα/β and IκBα, increase expression of RKIP and Bax and decrease expression of Mcl-1, Bcl-xL, Bcl-2, and phospho-BAD in target cells. The subject DNL complexes show ECvalues for inhibiting tumor cell growth in the low nanomolar or even sub-nanomolar concentration range.


Find Patent Forward Citations

Loading…